OMIX3

OMIX3 will provide the first mass spectrometry platform for undertaking integrated, accredited, multi-omic analysis of clinical samples in Australia. This disease-agnostic, open-access platform will allow parallel collection of proteomics, metabolomics and lipidomics data on a range of human sample types (including plasma, PBMC, stool and saliva). It will complement and add value to existing clinical genomics sequencing facilities.

OMIX3 will address a key unmet medical need through the provision of an end-to-end solution for integrated multi-omics analysis, from the point of biospecimen collection, to biobanking, automated sample preparation, parallel multi-omic analysis and secure, scalable data analysis tailored for clinical and population level cohorts of variable size. OMIX3 will underpin a major longitudinal study of healthy Australian adults (Px4 Health), designed to identify novel protein/small molecule (metabolites/lipid) biomarkers of aging and a wide range of chronic diseases that represent a substantial burden on the healthcare system. OMIX3 will also support national MRFF, NHMRC and Victorian Government/industry funded flagship projects in rare genetic diseases, infectious diseases & pandemic preparedness, delivering a step-change in clinical diagnostics and predictive health outcomes at scale.

OMIX3 is being led and administered by the Melbourne School of Psychological Sciences, where the project’s Principal Investigator (PI), Prof Olivia Carter, is situated. Prof Bernie Pope (Melbourne Bioinformatics/Australian BioCommons) is the Digital Infrastructure Platform Lead for OMIX3 and a CI on the project. Dr Gayle Philip (Melbourne Bioinformatics) is managing the end-to-end integration between Data Commons and the OMIX3 platform, working closely with CI Prof Kim-Anh Lê Cao (Melbourne Integrative Genomics).